Get online perscription for adderall and oxycontin, from oxycontin withdrawal, strattera adderall

Get online perscription for adderall and oxycontin

We develop and manufacture biosimilar products based on recombinant DNA ("rDNA") and monoclonal antibodies ("mAb"). We have launched six indigenously developed rDNA products and are in the process of developing two of these biosimilars in partnership with Apotex Inc., Canada ("Apotex") for markets in Europe, Turkey, Canada and the United States. We also have several rDNA and mAb based biosimilars in our "under development" pipeline. Our biopharmaceutical manufacturing facility was approved by European authorities in 2007 and subsequently in 2013. In addition, our facilities have been approved by various international regulatory authorities, including WHO, ANVISA, MCC and GCC.

We own and operate ten manufacturing facilities, of which eight are located in India, one in Mexico and a retesting laboratory, QP (qualified person) release site and fully automated packaging plant and warehouse at our facility in the U.K. Amongst them, our facilities have received approvals from various prominent international regulatory bodies, including from the United States Food and Drug Administration ("FDA"). We believe that each of our facilities is designed, equipped and operated to deliver high quality products within defined cost and delivery schedules. Our income and profit after tax for fiscal 2012 were ' 27,798.0 million and ' 2,961.2 million, respectively, representing growth of 40.6% and 56.5%, respectively, as compared to fiscal 2011. Our income and profit after tax for the nine month period ended December 31, 2012 were ' 27,149.0 million and ' 3,134.2 million, respectively. Our domestic and international pharmaceutical sales contributed 53.6% and 42.8%, respectively, of our revenue from operations for fiscal 2012 and 48.3% and 48.4%, respectively, of our revenue from operations for the nine month period ended December 31, 2012 (the remainder of our revenue from operations comprises sales of services, which are not divided into domestic and international sales, export incentives and other operating revenue). STRENGTHS • Strong focus on growth-oriented therapy areas in India. • Significant focus on research and development efforts.

STRATEGIES We intend to strengthen our position across identified therapy areas in India internationally in regulated and semi-regulated markets in order to achieve and further expand our operations long-term sustainable growth and increase shareholder value.

Our principal strategies and initiatives to achieve these objectives are set out below. • Growth and continued commercialization of our biosimilars pipeline. • Pursuing value added acquisitions and expanding through collaborations and joint ventures. No. Particulars Page 1 Standalone summary statement of assets and liabilities of the Company, as restated S-2 2 Standalone summary statement of profits and losses of the Company, as restated S-3 3 Standalone summary statement of cash flows of the Company, as restated S-4 4 Consolidated summary statement of assets and liabilities of the Company, as restated S-6 5. Consolidated summary statement of profits and losses of the Company, as restated S-7 6. Consolidated summary statement of cash flows of the Company, as restated S-8 As At As At As At As At As At As At As At 31.03.08 31.03.09 31.03.10 31.03.11 31.03.12 31.12.11 31.12.12 A Non-current assets Fixed assets Tangible assets 1,739.8 1,950.6 1,935.0 2,080.8 2,680.9 2,365.6 5,941.6 Intangible assets 252.1 240.7 259.2 185.2 154.5 237.9 3,191.3 Capital work-in-progress 7.7 28.5 72.4 397.7 420.8 539.4 901.5 Intangible Assets under Development 162.7 175.6 341.9 467.7 525.0 485.8 1,863.6 Total Fixed Assets 2,162.3 2,395.4 2,608.5 3,131.3 3,781.2 3,628.7 11,898.0 Non-current Investments 1,099.4 2,107.6 2,769.2 6,505.1 8,682.6 6,505.1 4,886.8 Long-term Loans and Advances 566.1 1,218.9 2,325.1 4,175.8 3,286.1 4,096.6 3,369.2 Other Non-current Assets 1.8 1.8 2.3 27.0 51.4 52.8 131.8 Total Non-current Assets 3,829.6 5,723.7 7,705.2 13,839.2 15,801.3 14,283.2 20,285.8 B Current Assets Current Investments - - - - - - 48.0 Trade Receivables 1,484.6 1,get online perscription for adderall and oxycontin 891.3 2,992.6 3,924.5 6,934.2 6,395.0 10,128.1 Cash and Bank Balances 190.6 155.0 190.9 175.1 189.3 243.3 266.9 Short-term Loans and Advances 587.1 991.6 1,050.4 1,222.6 1,538.4 1,694.1 2,221.2 Inventory 1,622.5 2,119.6 2,475.6 3,505.4 4,646.1 4,213.4 5,801.0 Total Current Assets 3,884.8 5,157.5 6,709.5 8,827.6 13,308.0 12,545.8 18,465.2 C Total Assets (C = A + B ) 7,714.4 10,881.2 14,414.6 22,666.8 29,109.3 26,829.0 38,751.0 D Non-current Liabilities Long-term Borrowings 892.6 954.6 2,068.9 3,984.4 3,075.5 2,929.5 1,617.8 Deferred Tax Liabilities (net) 283.5 297.3 208.2 190.8 195.9 180.0 520.8 Other long-term Liabilities 131.0 130.6 130.9 168.3 170.2 169.2 192.0 Long-term Provisions 152.0 88.2 323.0 306.7 323.7 374.1 445.0 Total Non-current Liabilities 1,459.1 1,470.7 2,731.0 4,650.2 3,765.3 3,652.8 2,775.6 E Current Liabilities Short-term Borrowings 1,581.2 2,710.8 1,547.6 3,943.2 5,504.7 5,365.0 5,079.4 Trade Payables 1,157.4 1,640.5 2,949.4 3,379.9 4,512.4 4,076.3 7,819.3 Other Current Liabilities 276.1 653.5 674.0 1,101.4 1,942.3 1,521.9 1,300.7 Short-term Provisions 55.1 60.5 120.8 240.5 240.5 - - Total Current Liabilities 3,069.8 5,065.3 5,291.8 8,665.0 12,199.9 10,963.2 14,199.4 F Total Liabilities (F = D + E) 4,528.9 6,536.0 8,022.8 13,315.2 15,965.2 14,616.0 16,975.0 G Net Worth ( C - F ) 3,185.5 4,345.2 6,391.8 9,351.7 13,144.1 12,213.0 21,776.0 H Represented by: Shareholders' Funds Share Capital 469.5 517.4 518.7 1,038.8 1,034.8 1,034.8 1,144.4 Share Application Money Pending Allotment 3.3 1.3 - - - - - Reserves and Surplus 2,712.7 3,826.5 5,873.1 8,312.9 12,109.3 11,178.2 20,631.6 Networth 3,185.5 4,345.2 6,391.8 9,351.7 13,144.1 12,213.0 21,776.0 Year Ended Year Ended Year Ended Year Ended Year Ended Period Period Ended Ended 31.03.08 31.03.09 31.03.10 31.03.11 31.03.12 31.12.11 31.12.12 Income Income from Operations 10,075.5 12,066.1 16,413.1 19,553.3 26,344.9 19,315.5 26,368.9 Less: Duties and Taxes (174.5) (96.8) (60.7) (79.6) (122.7) (84.5) (119.5) 9,901.0 11,969.3 16,352.4 19,473.8 26,222.2 19,231.0 26,249.4 Other Income 37.9 99.8 61.3 203.1 296.4 124.9 106.0 Total Income 9,938.9 12,069.1 16,413.7 19,676.8 26,518.6 19,355.9 26,355.3 Expenditure Purchases of Traded Goods 3,223.9 3,810.3 4,482.2 5,830.1 7,500.9 5,414.8 6,584.8 Materials Consumed 2,042.1 2,299.5 3,311.1 4,210.4 5,857.0 4,309.5 5,662.4 Decrease / (Increase) in Inventories (25.8) (269.3) 33.3 (720.1) (905.6) (576.6) 301.6 Manufacturing Expenses 294.5 378.9 450.2 518.6 738.4 533.7 1,095.7 Employee Benefits Expenses 712.6 878.5 1,284.3 1,457.6 1,895.9 1,449.1 2,230.0 Administrative and General Expenses 723.0 1,143.5 1,319.6 1,403.3 1,105.0 830.0 891.9 Selling and Marketing Expenses 1,638.7 2,089.4 2,658.4 3,223.7 4,266.3 3,046.0 3,402.3 Total Expenditure 8,609.0 10,330.8 13,539.1 15,923.6 20,457.9 15,006.5 20,168.7 Earnings before Interest, Tax, Depreciation and Amortisation 1,329.9 1,738.3 2,874.6 3,753.2 6,060.7 4,349.4 6,186.7 Depreciation and Amortisation 172.3 202.6 244.5 269.3 302.3 223.8 533.9 Finance Costs 223.9 229.4 312.4 419.6 775.0 572.1 431.5 Restated Profit Before Tax 933.7 1,306.3 2,317.7 3,064.3 4,983.4 3,553.5 5,221.3 Less: Provision for Taxation - Current Tax (22.9) (54.2) (206.5) (280.1) (545.4) (303.0) (599.8) - Deferred T ax (42.6) (16.8) 56.2 17.3 (5.1) 10.8 60.0 - Fringe Benefit Tax (57.1) (60.1) - - - - - Total Tax Expense (122.6) (131.1) (150.3) (262.7) (550.5) (292.2) (539.8) Net Profit As Per Restated Audited Financial Statements 811.2 1,175.2 2,167.5 2,801.6 4,432.9 3,261.3 4,681.5 Year ended Year ended Year ended Year ended Year ended Period Period 31.03.2008 31.03.2009 31.03.2010 31.03.2011 31.03.2012 ended ended 31.12.11 31.12.12 A CASH FLOWS FROM OPERATING ACTIVITIES Net Profit Before Tax 933.7 1,306.3 2,317.7 3,064.3 4,983.4 3,553.5 5,221.3 Adjustments to reconcile Profit Before Tax to Net Cash Flows: Interest Income (4.9) (8.5) (13.5) (118.7) (208.0) (67.7) (29.6) Excess Provision written back - - 29.7 Loss on Sale of Fixed Assets (net) 1.0 2.6 3.8 4.8 4.1 4.1 10.2 Sundry Balances written- off 15.1 17.4 2.6 0.2 (0.2) (0.3) (0.0) Provision for Impairment of assets - - - - - - 141.9 Depreciation and Amortisation 172.3 202.6 244.5 269.3 302.3 223.8 533.9 Interest Expenses 190.1 188.4 255.6 381.0 712.1 519.5 391.2 Provision for Diminision in Value of Investments 54.4 Operating Cash Flows before Working Capital Changes 1,307.3 1,708.8 2,865.1 3,600.9 5,793.7 4,232.9 6,298.6 Working Capital Adjustments: Change in Inventories (89.1) (497.1) (355.9) (1,029.9) (1,140.7) (708.0) (238.1) Change in Trade Receivables (331.1) (424.1) (1,103.9) (932.1) (3,009.5) (2,470.2) (2,611.1) Change in Loans and Advances & Other Current Assets (531.8) (1,057.4) (1,165.5) (2,047.6) 549.4 (418.1) (1,123.9) Change in Current Liabilities and Provisions 200.9 796.3 1,434.2 875.6 1,989.4 1,224.3 1,528.3 Cash Flows generated from Operations 556.2 526.6 1,674.0 467.0 4,182.3 1,860.9 3,853.8 Direct Taxes paid (73.8) (117.7) (149.1) (245.4) (532.3) (295.2) (454.8) Net Cash Flows generated from Operating Activities 482.4 408.9 1,524.9 221.6 3,650.0 1,565.7 3,399.0 B CASH FLOWS FROM INVESTING ACTIVITIES Purchase of Fixed Assets (583.3) (456.4) (476.9) (817.2) (964.6) (731.7) (4,793.3) Proceeds from sale of fixed assets 16.8 18.2 15.6 20.3 8.3 6.4 12.2 Interest Received 4.9 8.6 13.0 118.3 209.4 67.9 (5.1) Investments in (646.5) (1,008.2) (716.0) (get online perscription for adderall and oxycontin 3,735.8) (2,177.5) (0.0) 482.7 Net Cash Flows uted in Investing Activities (1,208.2) (1,437.8) (1,164.5) (4,414.4) (2,924.4) (657.4) (4,303.5) Year ended Year ended Year ended Year ended Year ended Period Period 31.03.2008 31.03.2009 31.03.2010 31.03.2011 31.03.2012 ended ended 31.12.11 31.12.12 C CASH FLOWS FROM FINANCING Redemption of Preference shares / Issue of Equity Shares 25.9 45.9 0.0 398.7 (400.0) (400.0) 3,000.0 Share issue expenses - - - (24.4) (25.7) (26.0) - Proceeds from / Repayments of Short Term Borrowings 113.5 1,129.5 (1,163.1) 2,395.6 1,561.5 1,421.8 (574.6) Proceeds from / Repayments of Long Term Borrowings 814.0 62.0 1,114.3 1,915.5 (908.9) (1,054.9) (1,175.8) Interest paid (190.1) (189.1) (215.2) (387.6) (697.8) (540.5) (37.8) Dividend paid including Tax on Dividend (110) (55.0) (60.5) (120.9) (240.5) (240.5) (240.5) Net Cash Flows generated from / (used in) Financing Activities 752.3 993.3 (324.5) 4,177.0 (711.4) (840.1) 971.3 Net (Decrease) / Increase in Cash or Cash Equivalents (A + B + C) 26.5 (35.6) 35.9 (15.8) 14.2 68.2 66.8 Cash and Cash Equivalents at the Beginning of the Year 163.5 190.6 155.0 190.9 175.1 175.1 189.3 Cash and Cash Equivalents Received due to Merger 0.6 10.8 Cash and Cash Equivalents at the End of the Period 190.6 155.0 190.9 175.1 189.3 243.3 266.9 Components of Cash and Cash Equivalents: Cash on Hand 1.4 1.5 5.5 2.2 1.1 3.3 5.6 Balances with Banks - On Current Accounts 169.1 143.5 166.6 157.2 174.5 227.8 229.5 - On Deposit Accounts 20.1 10.0 18.8 15.7 13.7 12.2 31.8 190.6 155.0 190.9 175.1 189.3 243.3 266.9 As At As At As At As At As At As At As At 31.03.08 31.03.09 31.03.10 31.03.11 31.03.12 31.12.11 31.12.12 A Non-current assets Fixed assets Tangible assets 2,003.8 2,545.8 3,072.2 6,087.0 6,973.0 6,464.7 7,216.6 Intangible assets 782.2 1,315.3 1,570.9 4,678.9 5,143.2 5,132.1 3,075.4 Capital work-in-progress 76.9 761.5 1,501.1 712.9 793.4 1,136.7 1,045.2 Intangible Assets under Development 436.1 218.1 458.5 1,987.2 2,126.1 2,090.1 2,015.1 3,299.0 4,840.7 6,602.7 13,466.0 15,035.7 14,823.6 13,352.3 Non-current Investments 0.0 0.0 0.0 142.4 142.4 142.4 142.4 Deferred Tax Assets (net) 3.6 11.5 12.5 83.5 461.6 - 543.7 Long-term Loans and Advances 363.4 568.0 644.6 714.9 1,009.5 833.4 1,143.4 Trade receivables - 0.4 10.3 0.7 - 2.3 1.7 Other Non-Current Assets 2.0 1.9 2.4 27.1 51.5 52.9 130.3 Total Non Current Assets 3,668.0 5,422.5 7,272.5 14,434.6 16,700.7 15,854.6 15,313.8 B Current Assets Current Investments - - 172.6 - - - 48.0 Inventories 1,711.1 2,530.2 3,113.8 5,272.1 7,374.6 7,165.7 7,504.4 Trade Receivables 1,478.2 1,936.8 2,789.4 4,022.0 5,288.0 6,074.1 6,867.1 Cash and Bank Balances 449.9 663.1 449.1 508.2 355.1 445.1 672.8 Short-term Loans and Advances 608.9 870.1 1,026.9 1,782.7 2,229.5 2,475.2 2,969.7 Other Current Assets - - - 0.1 0.0 - - Total Current Assets 4,248.1 6,000.2 7,551.8 11,585.1 15,247.2 16,160.1 18,062.0 C Total Assets (C = A + B ) 7,916.1 11,422.7 14,824.3 26,019.7 31,947.9 32,014.7 33,375.8 D Non-current Liabilities Long-term Borrowings 877.9 1,202.5 2,725.6 4,169.0 3,530.5 3,754.4 2,102.6 Deferred Tax Liabilities (net) 290.2 319.3 292.8 574.9 611.8 675.1 567.9 Other long-term Liabilities 131.0 141.5 133.0 188.1 172.4 191.3 195.0 Long-term Provisions 176.2 222.0 410.1 608.4 669.3 699.4 878.7 Total Non Current Liabilities 1,475.3 1,885.3 3,561.5 5,540.4 4,984.0 5,320.2 3,744.2 E Current Liabilities Short-term Borrowings 1,598.3 2,747.5 1,773.0 4,478.4 6,204.8 6,201.2 5,237.6 Trade Payables 1,590.5 2,162.1 2,881.5 3,419.5 4,826.1 5,118.9 5,657.6 Other Current Liabilities 250.3 516.6 812.1 1,592.1 2,652.9 2,547.4 1,901.9 Short-term Provisions 55.2 60.5 121.1 253.5 243.0 49.4 88.0 Total Current Liabilities 3,494.3 5,486.7 5,587.7 9,743.5 13,926.8 13,916.9 12,885.1 F Total Liabilities (F = D + E ) 4,969.6 7,372.0 9,149.2 15,283.9 18,910.8 19,237.1 16,629.3 Net Worth ( C - F ) 2,946.5 4,050.7 5,675.1 10,735.8 13,037.1 12,777.6 16,746.5 G Represented get online perscription for adderall and oxycontin by: Shareholders' Funds Share Capital 469.5 517.4 518.7 1,038.8 1,034.8 1,034.8 1,144.4 Reserves and Surplus 2,448.6 3,490.5 5,067.3 8,214.1 10,481.1 10,242.5 15,564.2 Minority Interest 25.1 41.5 89.1 1,482.9 1,521.2 1,500.3 37.9 Share Application Money Pending Allotment 3.3 1.3 - 2,946.5 4,050.7 5,675.1 10,735.8 13,037.1 12,777.6 16,746.5 Year Year Year Year Year Period Period Ended Ended Ended Ended Ended Ended Ended 31.03.08 31.03.09 31.03.10 31.03.11 31.03.12 31.12.11 31.12.12 INCOME Revenue from Operations 9,411.2 11,390.9 16,246.9 19,776.0 27,887.6 20,883.1 27,165.3 Less: Duties and Taxes 174.5 118.7 60.7 214.5 215.8 130.9 127.7 9,236.7 11,272.2 16,186.2 19,561.5 27,671.8 20,752.2 27,037.6 Other income 39.4 95.8 87.5 206.3 126.2 84.1 111.4 Total Income 9,276.1 11,368.0 16,273.7 19,767.8 27,798.0 20,836.3 27,149.0 EXPENDITURE Purchases of Traded Goods 1,871.6 2,424.3 2,579.4 3,270.9 4,060.1 3,643.9 3,227.6 Materials Consumed 2,533.3 2,940.8 4,121.1 5,634.1 7,751.1 5,631.9 6,601.2 Decrease / (Increase) in Inventories (79.4) (549.2) (138.0) (1,582.0) (1,589.2) (1,528.4) 390.9 Manufacturing Expenses 362.7 500.2 634.5 889.0 1,469.4 1,158.9 1,673.6 Employee Benefits Expenses 830.5 1,097.4 1,774.8 2,414.4 3,505.5 2,650.1 3,281.4 Administrative and General Expenses 794.2 1,289.2 1,492.6 1,846.6 1,976.7 1,636.0 1,852.1 Selling and Marketing Expenses 1,640.7 2,133.9 2,776.6 3,727.1 5,355.0 3,706.9 4,175.5 7,953.6 9,836.6 13,241.0 16,200.1 22,528.6 16,899.3 21,202.3 Earnings before Interest, Tax, Depreciation and Amortisation 1,322.5 1,531.4 3,032.7 3,567.7 5,269.4 3,937.0 5,946.7 Depreciation and Amortisation Expenses 193.1 241.0 417.2 514.6 757.6 566.2 701.0 Depreciation Adjustment (Refer Annexure 4 (b)) (12.3) (10.2) (34.8) 55.3 (4.9) (2.6) Finance Costs 228.2 237.7 327.3 519.5 948.6 667.1 501.7 Profit Before Exceptional Item 913.5 1,062.9 2,323.0 2,478.3 3,568.1 2,703.7 4,746.6 Less Exceptional Item 621.3 Restated Profit Before Tax 913.5 1,062.9 2,323.0 2,478.3 3,568.1 2,703.7 4,125.3 Less: Provision for get online perscription for adderall and oxycontin Taxation - Current Tax 86.1 135.5 302.7 343.9 854.7 566.1 1,076.0 - Deferred Tax 45.9 11.5 12.5 154.0 (354.1) 49.5 (162.9) Net Profit for the period before Minorty Interest 781.5 915.9 2,007.8 1,980.4 3,067.5 2,088.1 3,212.2 Less : Minority interest (28.8) (32.3) (49.6) (88.6) (106.3) (75.5) (78.0) Net Profit As Per Restated Financial Statements 752.7 883.6 1,958.2 1,891.8 2,961.2 2,012.6 3,134.2 ^^_JnMillions) Year Year Year Year Year Period Period Ended Ended Ended Ended Ended Ended Ended 31.03.08 31.03.09 31.03.10 31.03.11 31.03.12 31.12.11 31.12.12 A.



Delivery florida online pharmacy phentermine
Phentermine cymbalta
Dm hydrocodone promethazine syrup